Fennec Pharmaceuticals presents new PEDMARK research at 2026 ASCO meeting
Fennec announced four independent studies evaluating PEDMARK (sodium thiosulfate) across multiple patient populations at ASCO 2026, expanding evidence for broader use beyond pediatric patients. The research demonstrates potential to reduce cisplatin-induced hearing loss in adoles
View filing at SEC.gov →